Crinetics Pharmaceuticals (NASDAQ: CRNX)
Crinetics Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Crinetics Pharmaceuticals Company Info
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
News & Analysis
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Despite good results in phase 3 trials, there are barriers to its drug candidate's success.
Why Crinetics Pharmaceuticals Stock Soared This Week
A positive late-stage trial readout fueled a major rally in the drugmaker's shares.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.